Takeda Pharmaceutical Co Ltd (NYSE:TAK) saw its stock price plummet 5.08% in pre-market trading on Thursday following the release of its second-quarter earnings report and updated full-year outlook. The Japanese drugmaker's results fell short of analyst expectations, prompting concerns among investors.
For the second quarter of fiscal year 2025, Takeda reported adjusted earnings per American Depositary Share (EPADS) of 43 cents, missing the analyst consensus estimate of 44 cents. This represents a 4.44% decrease from the same period last year. The company's quarterly sales also disappointed, coming in at $7.52 billion, falling short of the expected $8.08 billion and marking a 4.82% year-over-year decline.
Adding to investor concerns, Takeda revised its full-year 2025 outlook downward. The company lowered its core revenue guidance from 4.53 trillion yen to 4.50 trillion yen and reduced its core operating profit forecast from 1.14 trillion yen to 1.13 trillion yen. Takeda cited impairment charges related to discontinued cell-therapy research and foreign exchange impacts as reasons for the adjustment. The pharmaceutical giant also reported a net loss of 11.8 billion yen for the quarter, a stark contrast to the 92.0 billion yen profit recorded in the same period last year. These factors collectively contributed to the significant drop in Takeda's stock price as investors reassessed the company's near-term prospects.
Comments